Merck's Dual-Action Bet Reshapes the Multi-Billion Dollar MASH Race

DENVER, CO – November 09, 2026 — For the modern biopharmaceutical enterprise, the blockbuster GLP-1 market has rapidly evolved from a gold rush in weight loss to a highly strategic war for targeted organ rescue. Nowhere is this shift more evident than in the race to treat metabolic dysfunction-associated steatohepatitis (MASH). Once an overlooked, silent epidemic, MASH has become a central battleground for corporate strategy and market dominance.

Merck has officially staked its claim in this lucrative arena. At The Liver Meeting (TLM) in Denver, the company unveiled compelling Phase 2b clinical trial data for efinopegdutide, an investigational injectable GLP-1/glucagon receptor co-agonist. Simultaneously published in The Lancet, the results demonstrate that Merck is not merely participating in the incretin boom—it is attempting to engineer a more sophisticated, dual-action weapon specifically designed to reverse complex liver scarring.

By translating a nuanced biological mechanism into a tangible clinical advantage, Merck is signaling to investors and competitors alike that the next era of cardiometabolic dominance will belong to those who can master disease resolution, not just weight management.

Beyond Weight Loss: The Dual Incretin Strategy

The scientific premise behind efinopegdutide represents a critical pivot in drug development. While traditional GLP-1 agonists like semaglutide have revolutionized the treatment of diabetes and obesity through appetite regulation and insulin sensitivity, they have shown limitations in directly addressing severe liver fibrosis. Efinopegdutide bridges this gap by co-activating both GLP-1 and glucagon receptors.

This dual mechanism is designed to combine the metabolic benefits of GLP-1 with the enhanced energy expenditure and direct hepatic lipid metabolism driven by glucagon. In simpler terms: while GLP-1 reduces overall body weight, glucagon acts directly on the liver to burn accumulated fat and halt the inflammatory cascade.

The Phase 2b MK-6024-013 trial results validate this hypothesis. Evaluating 381 adults with biopsy-confirmed MASH and stage F2 or F3 liver fibrosis over 52 weeks, the study met its primary efficacy endpoint with resounding statistical significance. MASH resolution without worsening of fibrosis was achieved by 56%, 63%, and 61% of patients on the 4 mg, 7 mg, and 10 mg weekly doses, respectively. In stark contrast, the placebo group saw only a 13% resolution rate.

Crucially, the trial included an active reference arm of open-label semaglutide (2.4 mg), which achieved a 45% resolution rate. By outperforming a pure GLP-1 agonist, Merck has provided hard evidence that the addition of glucagon receptor activation creates a distinct competitive moat.

“MASH poses a substantial risk of progression to cirrhosis and ultimately liver failure, underscoring the urgent need for new treatment options,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer at Merck Research Laboratories. “We are highly encouraged by these results which add to the evidence that efinopegdutide, a distinct GLP-1/glucagon receptor co-agonist, has the potential to provide clinically meaningful responses for MASH resolution and fibrosis regression.”

The MASH Race Heats Up: Market Dynamics and Licensing Masterstrokes

To understand the business intelligence behind Merck's clinical data, one must look at the broader market landscape. MASH affects an estimated 5% of the global population, driven by rising rates of metabolic syndrome. For decades, the disease was a commercial graveyard for pharmaceutical companies, marked by high-profile trial failures.

The regulatory ice was finally broken in early 2024 with the FDA approval of Madrigal Pharmaceuticals' Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist. While Rezdiffra established a critical regulatory pathway, its efficacy—achieving MASH resolution in roughly 26% to 37% of patients—left ample room for disruption.

Enter the heavyweights. Eli Lilly is aggressively advancing its dual GIP/GLP-1 agonist, tirzepatide, which showed roughly 52% to 63% MASH resolution in its SYNERGY-NASH trial. Boehringer Ingelheim, partnered with Zealand Pharma, is pushing survodutide, another GLP-1/glucagon co-agonist that has posted formidable early-stage numbers.

Merck's entry into this oligopoly is the result of a highly calculated corporate strategy. Efinopegdutide was not developed entirely in-house; it was in-licensed from South Korea's Hanmi Pharmaceutical in 2016. Merck secured worldwide rights (excluding Korea and China) for a mere $10 million upfront, paired with up to $860 million in milestone payments and tiered royalties. In the context of a MASH market projected to exceed $20 billion annually by the next decade, this licensing agreement stands as a masterclass in risk-adjusted portfolio expansion.

Decoding the Data: The 7mg 'Goldilocks' Zone and Patient Realities

While the headline efficacy numbers are stellar, a granular analysis of the trial data reveals the nuanced realities of drug development, specifically regarding tolerability and dose optimization.

The trial tracked a key secondary endpoint: meaningful improvements in fibrosis of at least one stage without worsening of steatohepatitis. Here, the 7 mg dose emerged as the clear victor, achieving a 52% response rate compared to 43% for the 4 mg dose and 21% for placebo.

However, the highest dose—10 mg—exhibited a paradoxical drop in efficacy, achieving only a 34% fibrosis improvement rate. This anomaly is directly tied to the drug's safety and tolerability profile.

Like other incretin-based therapies, efinopegdutide is associated with gastrointestinal adverse events. Nausea occurred in 44% of participants on the 10 mg dose, compared to 39% on the 7 mg dose and 29% on the 4 mg dose. More tellingly, the discontinuation rate due to adverse events spiked to 11% in the 10 mg cohort, compared to just 4% for the 7 mg group and 3% for the 4 mg group.

Independent clinical trial investigators familiar with incretin mechanisms note that pushing dosages too high often results in diminished returns. Severe gastrointestinal distress can lead to poor patient compliance, missed doses, and ultimately, a failure to achieve the sustained drug exposure required to reverse deep-seated fibrotic tissue over a 52-week period.

“MASH is a chronic inflammatory liver disease, with limited treatment options. Achieving disease resolution establishes an important treatment goal,” said Professor Jörn M. Schattenberg, M.D., Department of Internal Medicine II, Saarland University Medical Center. “The improvements observed in fibrosis grading following efinopegdutide treatment in this study are notable and underscore its potential as a therapeutic option in patients with MASH and fibrosis.”

The data clearly points to the 7 mg dose as the optimal therapeutic window—balancing aggressive disease resolution with manageable tolerability. This insight will be critical as Merck negotiates its Phase 3 trial designs with regulatory authorities.

The Strategic Horizon for the Enterprise

Armed with Fast Track designation from the U.S. FDA, Merck is now positioned to accelerate efinopegdutide into pivotal Phase 3 trials. This development is not occurring in a vacuum; it is a core component of Merck's broader imperative to diversify its revenue streams and solidify its cardiometabolic portfolio.

By proving that dual receptor co-agonism can effectively remodel fibrotic liver tissue, Merck is doing more than advancing a clinical asset; it is redefining the standard of care in a highly competitive sector. As the pharmaceutical industry increasingly views metabolic health through a holistic, multi-organ lens, the companies that can successfully navigate the tightrope of high efficacy and patient tolerability will ultimately capture the market.